ALDX
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
471.99M
GET INTRADAY SIGNALS
ALDX Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
48 days until earnings call
+Compare
ALDX
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
471.99M

ALDX Price Prediction, Aldeyra Therapeutics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
ALDX Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 23, 2023

Aroon Indicator for ALDX shows an upward move is likely

ALDX's Aroon Indicator triggered a bullish signal on March 23, 2023. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator showed a similar pattern. In 140 of the 161 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on March 14, 2023. You may want to consider a long position or call options on ALDX as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALDX just turned positive on March 22, 2023. Looking at past instances where ALDX's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

ALDX moved above its 50-day moving average on February 15, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALDX crossed bullishly above the 50-day moving average on February 16, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ALDX advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALDX broke above its upper Bollinger Band on March 23, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.514) is normal, around the industry mean (21.708). P/E Ratio (0.000) is within average values for comparable stocks, (125.534). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.749). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (303.071).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

AI
A.I. Advisor
published Earnings

ALDX is expected to report earnings to rise 47.82% to -32 cents per share on May 11

Aldeyra Therapeutics ALDX Stock Earnings Reports
Q1'23
Est.
$-0.33
Q4'22
Beat
by $0.09
Q3'22
Beat
by $0.09
Q2'22
Beat
by $0.01
Q1'22
Beat
by $0.03
The last earnings report on March 09 showed earnings per share of -21 cents, beating the estimate of -31 cents. With 2.38M shares outstanding, the current market capitalization sits at 471.99M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.96B. The market cap for tickers in the group ranges from 160 to 331.75B. NONOF holds the highest valuation in this group at 331.75B. The lowest valued company is CDXI at 160.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 0%. CALC experienced the highest price growth at 1,040%, while MMIRF experienced the biggest fall at -92%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was -64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: -2 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published General Information

General Information

a developer of therapeutics for eye diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
131 Hartwell Avenue
Phone
+1 781 761-4904
Employees
15
Web
https://www.aldeyra.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NWJFX96.561.21
+1.27%
Nationwide NYSE Arca Tech 100 Idx InsSvc
LKBLX49.68N/A
N/A
LK Balanced Institutional
GCCSX28.49-0.12
-0.42%
Gabelli Small Cap Growth C
LBWAX16.75-0.10
-0.59%
BrandywineGLOBAL Div US Large Value A
UBVSX70.76-0.91
-1.27%
Undiscovered Managers Behavioral Val I

ALDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALDX has been loosely correlated with ALXO. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALDX jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALDX
1D Price
Change %
ALDX100%
+12.41%
ALXO - ALDX
49%
Loosely correlated
+1.46%
KRYS - ALDX
48%
Loosely correlated
+2.54%
CBAY - ALDX
47%
Loosely correlated
+1.82%
CANF - ALDX
46%
Loosely correlated
-1.77%
ADPT - ALDX
46%
Loosely correlated
-1.13%
More